Literature DB >> 30986105

A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine.

Bradley A Maron1,2, John J Ryan3.   

Abstract

Entities:  

Keywords:  World Health Organization; endothelin receptor antagonists; heart failure; hypertension, pulmonary; phosphodiesterase 5 inhibitors

Mesh：

Substances：

Year:  2019        PMID： 30986105     DOI： 10.1161/CIRCULATIONAHA.118.037613

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  9 in total

1.  Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy.

Authors:  Shelsey W Johnson; Kari R Gillmeyer; Rendelle E Bolton; Megan B McCullough; Shirley X Qian; Bradley A Maron; Elizabeth S Klings; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2022-07

2.  Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial.

Authors:  Bradley A Maron; Gaurav Choudhary; Rebekah L Goldstein; Eric Garshick; Matthew Jankowich; Troo J S Tucker; Kathleen A LaCerda; Brack Hattler; Edward C Dempsey; Ruxana T Sadikot; Shelley Shapiro; Sharon I Rounds; Ronald H Goldstein
Journal:  Pulm Circ       Date:  2022-03-14       Impact factor: 2.886

3.  Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.

Authors:  Kari R Gillmeyer; Seppo T Rinne; Mark E Glickman; Kyung Min Lee; Qing Shao; Shirley X Qian; Elizabeth S Klings; Bradley A Maron; Joseph T Hanlon; Donald R Miller; Renda Soylemez Wiener
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-05-12

4.  Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances.

Authors:  Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 30.528

5.  Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic.

Authors:  John J Ryan; Lana Melendres-Groves; Roham T Zamanian; Ronald J Oudiz; Murali Chakinala; Erika B Rosenzweig; Mardi Gomberg-Maitland
Journal:  Pulm Circ       Date:  2020-04-29       Impact factor: 3.017

6.  SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension.

Authors:  Wei Sun; Ying Tang; Yi-Yin Tai; Adam Handen; Jingsi Zhao; Gil Speyer; Yassmin Al Aaraj; Annie Watson; Makenna E Romanelli; John Sembrat; Mauricio Rojas; Marc A Simon; Yingze Zhang; Janet Lee; Zeyu Xiong; Partha Dutta; Sathish Badu Vasamsetti; Dennis McNamara; Bryan McVerry; Charles F McTiernan; Frank C Sciurba; Seungchan Kim; Kerri Akaya Smith; Jeremy A Mazurek; Yuchi Han; Anjali Vaidya; Seyed Mehdi Nouraie; Neil J Kelly; Stephen Y Chan
Journal:  JACC Basic Transl Sci       Date:  2020-11-04

Review 7.  Management of Pulmonary Arterial Hypertension.

Authors:  Jennalyn D Mayeux; Irene Z Pan; John Dechand; Joshua A Jacobs; Tara L Jones; Stephen H McKellar; Emily Beck; Nathan D Hatton; John J Ryan
Journal:  Curr Cardiovasc Risk Rep       Date:  2020-11-18

8.  Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease.

Authors:  Kari R Gillmeyer; Donald R Miller; Mark E Glickman; Shirley X Qian; Elizabeth S Klings; Bradley A Maron; Joseph T Hanlon; Seppo T Rinne; Renda S Wiener
Journal:  Pulm Circ       Date:  2021-04-01       Impact factor: 3.017

9.  Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers.

Authors:  Hythem Nawaytou; Jeffrey R Fineman; Shahin Moledina; Dunbar Ivy; Steven H Abman; Maria J Del Cerro
Journal:  Pulm Circ       Date:  2021-02-09       Impact factor: 3.017
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.